首页 | 本学科首页   官方微博 | 高级检索  
检索        


Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
Authors:Walter Taal  Hendrika M Oosterkamp  Annemiek M E Walenkamp  Hendrikus J Dubbink  Laurens V Beerepoot  Monique C J Hanse  Jan Buter  Aafke H Honkoop  Dolf Boerman  Filip Y F de Vos  Winand N M Dinjens  Roelien H Enting  Martin J B Taphoorn  Franchette W P J van den Berkmortel  Rob L H Jansen  Dieta Brandsma  Jacoline E C Bromberg  Irene van Heuvel  Martin J van den Bent
Institution:1. Department of Neuro-oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands;2. Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, Netherlands;3. Clinical Trial Centre, Erasmus MC Cancer Institute, Rotterdam, Netherlands;4. Department of Medical Oncology, Medical Center Haaglanden, The Hague, Netherlands;5. Department of Medical Oncology, University Medical Center Groningen, Groningen, Netherlands;6. Department of Oncology, St Elisabeth Ziekenhuis, Tilburg, Netherlands;7. Department of Neurology, Catharina Hospital Eindhoven, Netherlands;8. Department of Oncology, VU University Medical Center, Amsterdam, Netherlands;9. Department of Internal Medicine, Isala Kliniek, Zwolle, Netherlands;10. Department of Neurology, Rijnstate, Arnhem, Netherlands;11. Department of Medical Oncology, University Medical Centre Utrecht, Utrecht, Netherlands;12. Department of Neurology, University Medical Center Groningen, Groningen, Netherlands;13. Department of Neurology, Medical Center Haaglanden, The Hague, Netherlands;14. Department of Oncology, Atrium MC Parkstad, Heerlen, Netherlands;15. Department of Oncology, Maastricht Universitair Medisch Centrum, Netherlands;p. Department of Neuro-oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
Abstract:
Keywords:
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号